• Home
  • Drug utilization study Publications

Drug utilization study Publications

Drug utilization study Publications

  • Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel-proton pump inhibitor interaction.Abstract

    Safety concerns of the concomitant use of clopidogrel-proton pump inhibitors (PPIs) were published in 2009 and 2010 by the medicines regulatory agencies, including a direct healthcare professional communication. We examined the association between various safety statements and prescription behavior for gastroprotective drugs in naive patients in the Netherlands during the years 2008-2011

    Pharmacology Research & Perspectives. July 18; 4 (4): e00242.
  • Use of oral contraceptives in three European countries: a population-based multi-database study.Abstract

    OBJECTIVES: The aim of the study was to assess the prevalence of oral contraceptive (OC) use, user characteristics and prescribing patterns by accessing health care databases of three European countries. METHODS: A retrospective study was performedfrom 2009 to 2010 in three general practice (GP) databases from the Netherlands, UK and Italy and in one database of linked pharmacy and hospitalisation data in the Netherlands

    Bezemer ID, Verhamme KM, Gini R, Mosseveld M, Rijnbeek PR, Trifiro G, Sturkenboom MC, Penning-van Beest FJ, Herings RM. Eur J Contracept Reprod Health Care. 2016 Feb; 21 (1): 81-7.
  • Anticoagulant Treatment after VTE in the Netherlands: A Retrospective Cohort Study.Abstract

    Background: The aim of the study was to describe initial anticoagulant treatment after venous thromboembolism (VTE) and relate this to the underlying risk factors, guidelines and recurrence rates.

    Bezemer ID, van den Berg EJ, Herings RMC, Bamber L, Penning-van Beest FJA, Folkerts K, Coppens M. J J Hemato. 2016 2 (2): 030.
  • Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.Abstract

    AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart dsease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug

    Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Acta Paediatr. 2015 Sep; 104 (9): 927-32.
  • Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project.Abstract

    PURPOSE: To examine patterns of outpatient and community antibiotic use among adults in five European countries. METHODS: We used healthcare data of 28.8 million adults from six population-based ARITMO project databases to ascertain information onystemic antibiotic use in Denmark (2000-2008), the Netherlands (1999-2010), Italy (2000-2010), the UK (1996-2009), and Germany (2004-2008)

    Mor A, Froslev T, Thomsen RW, Oteri A, Rijnbeek P, Schink T, Garbe E, Pecchioli S, Innocenti F, Bezemer I, Poluzzi E, Sturkenboom MC, Trifiro G, Sogaard M. Infection. 2015 Aug; 43 (4): 453-72.
  • Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands.Abstract

    AIM: The aim of the study was to document long term trends in oral antidiabetic drug (OAD) use among children and adolescents in the Netherlands. METHODS: A population-based cohort study was conducted using the Dutch PHARMO Database Network. All paients younger than 20 years old with at least one OAD dispensing were identified

    FazeliFarsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM, deBoer A, Mantel-Teeuwisse AK. Br J Clin Pharmacol. 2015 Aug; 80 (2): 294-303.
  • Trends in paediatric macrolide use in five European countries-a population-based study.Abstract

    PURPOSE: The study aims to analyse overall as well as subgroup-specific outpatient paediatric macrolide use in five European countries, including time trends of macrolide prescription rates, and to provide potential targets for future interventionsaiming to promote judicious macrolide use. METHODS: Macrolide prescription rates per 1000 person years to paediatric outpatients (

    Holstiege J, Ender s D, Schink T, Innocenti F, Oteri A, Bezemer I, Kaguelidou F, Molokhia M, Poluzzi E, Puccini A, Ulrichsen SP, Sturkenboom MC, Trifiro G, Garbe E. Eur J Clin Pharmacol. 2015 Aug; 71 (8): 991-9.
  • Dispensing of potentially teratogenic drugs before conception and during pregnancy: a population-based study.Abstract

    OBJECTIVE: To study the dispensing of potentially teratogenic drugs in the 12-month period before as well as during pregnancy in the Netherlands. DESIGN: Population-based study. SETTING: A cohort was constructed using a linkage between the PHARMO Dtabase Network and the Netherlands Perinatal Registry (PRN)

    Zomerdijk IM, Ruiter R, Houweling LM, Herings RM, Straus SM, Stricker BH. BJOG. 2015 Jul; 122 (8): 1119-29.
  • Long-term persistence with anti-osteoporosis drugs after fracture.Abstract

    Long-term persistence with anti-osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Those aged >/=80 years were at increased risk of earlydiscontinuation. Within 1 year after discontinuation, 24

    Klop C, Welsing PM, Elder s PJ, Overbeek JA, Souverein PC, Burden AM, van Onzenoort HA, Leufkens HG, Bijlsma JW, deVries F. Osteoporos Int. 2015 Jun; 26 (6): 1831-40.
  • Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes.Abstract

    AIMS/HYPOTHESIS: Adherence to glucose-lowering drug (GLD) treatment regimens is crucial for metabolic control and improving prognosis. Because a diagnosis of cancer might have an impact on adherence to medication, this study explored changes in adhrence to GLDs following a cancer diagnosis. METHODS: All new users of GLDs between 1998 and 2011 who lived in the Eindhoven Cancer Registry-PHARMO Database Network catchment area were selected

    Zander s MM, Haak HR, van Herk-Sukel MP, van dePoll-Franse LV, Johnson JA. Diabetologia. 2015 May; 58 (5): 951-60.